Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:13 PM ET 8-K
Financial Results Soundthinking, Inc. SSTI

Soundthinking Financial Results

SoundThinking reported third quarter 2026 financial results with revenue of $25.0 million, which remained flat year-over-year. The company reported a GAAP net loss of $8.5 million, widened from a $2.0 million loss in the prior year, largely due to costs associated with its pending acquisition by Transom Capital Group. The company expects to close the Transom Transaction, which values the company at up to $159 million including contingent value rights, in the fourth quarter of 2026.

Term
Q3 2026
4:13 PM ET Form 4
Insider Selling Motorola Solutions, Inc. MSI

Motorola Solutions SVP, COS to the Chairman & CEO Cynthia Yazdi Sells $2.22M of Stock

Cynthia Yazdi, SVP, COS to the Chairman & CEO, sold 4,227 shares of Motorola Solutions, Inc. at $524.59 to $524.78 a share (average $524.60) in 3 transactions, worth $2.22M in total on Nov 9, 2026. Shares held after the trade: 5,417 (-42.5%).

Value
$2.22M
Shares
4,227
Average price
$524.60
Role
SVP, COS to the Chairman & CEO
Holding change
-42.5%
Trade date
Nov 9, 2026
4:13 PM ET 8-K
Divestiture Apollo Commercial Real Estate Finance, Inc. ARI

Apollo Commercial Real Estate Finance Liquidating Trust Divestiture

Apollo Commercial Real Estate Finance, Inc. (ARI) completed its plan of liquidation by transferring all remaining assets and liabilities to the Apollo Commercial Real Estate Finance Liquidating Trust. ARI stockholders received non-transferable units of beneficial interest in the trust on a one-for-one basis, and ARI's common stock has been cancelled and deregistered from the SEC.

Term
through Nov 2029
4:13 PM ET 10-Q
Financial Results Planet 13 Holdings Inc. PLNH

Planet 13 Holdings Q3 2026 Results: Net Loss of $6.36M, Loss Narrows

Planet 13 Holdings reported a net loss of $20.0 million for the nine months ended September 30, 2026, an improvement from the $59.3 million loss in the prior year period. The company successfully exited all California operations during the quarter and is monitoring the impact of the U.S. Department of Justice's move to reclassify medical marijuana to Schedule III, which may alleviate Section 280E tax burdens.

Key figure
Net loss $6.36M
4:13 PM ET 10-Q
Financial Results Heartflow, Inc. HTFL

Heartflow Q3 2026 Results: Net Loss of $11.5M, Loss Narrows

Heartflow, Inc. reported a total asset base of $355.3 million as of September 30, 2026, with a significant accumulated deficit of $1.14 billion. The company remains focused on its Heartflow FFRCT and Plaque Analysis products while maintaining a liquid position of approximately $167.7 million in cash and short-term investments.

Key figure
Net loss $11.5M
4:13 PM ET 10-Q
Financial Results Serina Therapeutics, Inc. SER

Serina Therapeutics Q3 2026 Results: Net Loss of $7.91M, Loss Widens

Serina Therapeutics reported a net loss of $21.2 million for the nine months ended September 30, 2026, as it continues to invest in research and development. The company significantly strengthened its balance sheet during the period, increasing cash and cash equivalents to $19.4 million through private placements and equity facilities.

Key figure
Net loss $7.91M
4:13 PM ET 10-Q
Financial Results Antares Private Credit Fund

Antares Private Credit Fund Q3 2026 Results: Net Income $21.6M, Up 21.3% YoY

For the nine months ended September 30, 2026, Antares Private Credit Fund reported total investment income of $114.9 million and net investment income of $52.7 million. Net assets increased by $39.5 million from operations, though the fund experienced a net change in unrealized depreciation of $12.0 million during the period.

Key figure
Net income $21.6M · +21.3% YoY
4:12 PM ET 8-K
Financial Results Once Upon a Farm, PBC OFRM

Once Upon a Farm, PBC Financial Results

Once Upon a Farm reported Q3 2026 net sales of $89.1 million, a 35% increase year-over-year driven by 32% volume growth. The company narrowed its net loss to $3.8 million from $11.3 million in the prior year, though Adjusted EBITDA shifted to a $1.0 million loss due to lower gross margins from trade investments and product mix.

Term
Q3 2026

“Third quarter results demonstrated our ability to increase brand awareness and household penetration, deepen and expand retail reach, and deliver value added innovation. As more families consume our products in greater frequency, alongside disciplined investment and execution, we are on course to build the first truly baby through kid brand, with meaningful operating leverage and structurally higher margins as we scale.”

John Foraker, CEO and co-founder of Once Upon a Farm

“We are building one of the most compelling, durable growth platforms in food with increasing household penetration, strong consumer loyalty, attractive retail productivity, and significant opportunities to expand our reach in new categories relevant to our consumers.”

John Foraker, CEO and co-founder of Once Upon a Farm
4:12 PM ET 8-K
Loan & Debt Invesco Galaxy Solana ETF QSOL

Invesco Galaxy Solana ETF Debt Financing Update with Coinbase Credit, Inc.

The Invesco Galaxy Solana ETF entered into a Master Loan Agreement with Coinbase Credit, Inc. for a multiple-draw secured digital asset borrowing facility. The facility allows the Trust to borrow digital assets or cash, secured by a first-priority security interest in collateral held at Coinbase, to facilitate the Trust's SOL staking activities. Additionally, the Trust entered into a digital assets custody agreement with The Bank of New York Mellon to maintain segregated custody accounts for its SOL holdings.

Counterparty
Coinbase Credit, Inc.
4:12 PM ET 8-K
Financial Results Sensus Healthcare, Inc. SRTS

Sensus Healthcare Financial Results

Sensus Healthcare reported Q3 2026 revenue of $6.0 million, a 13% decrease year-over-year due to a shift in product mix and the absence of sales to a historically large customer. Despite lower revenue, gross margin improved significantly to 55% from 39.1% in the prior year, and the company reached a milestone of 1,000 SRT systems placed.

Term
Q3 2026

“Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability.”

Joseph Sardano, Chairman and Chief Executive Officer

“Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business.”

Joseph Sardano, Chairman and Chief Executive Officer
4:12 PM ET 10-Q
Financial Results Kodiak Sciences Inc. KOD

Kodiak Sciences Q3 2026 Results: Net Loss of $66.2M, Loss Widens

Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.

Key figure
Net loss $66.2M
4:12 PM ET 8-K
Dividend Lci Industries LCII

Lci Industries Dividend

LCI Industries announced that its Board of Directors has approved a regular quarterly cash dividend of $1.15 per share of common stock. The dividend is scheduled to be paid on December 11, 2026, to stockholders of record as of November 27, 2026.

4:12 PM ET Form 4
Insider Selling Teva Pharmaceutical Industries Ltd TEVA

Teva Pharmaceutical Industries See "Remarks" Mark Sabag Sells $1.97M of Stock

Mark Sabag, See "Remarks", sold 44,710 shares of Teva Pharmaceutical Industries Ltd at $44.14 a share, worth $1.97M in total on Nov 12, 2026. Shares held after the trade: 80,760 (-35.6%).

Value
$1.97M
Shares
44,710
Price
$44.14
Role
See "Remarks"
Holding change
-35.6%
Trade date
Nov 12, 2026
4:12 PM ET 10-Q
Financial Results Streamex Corp. STEX

Streamex Q3 2026 Results: Net Loss of $17.5M, Loss Widens

Streamex Corp. reported a significant increase in net loss to $78.7 million for the nine months ended September 30, 2026, compared to $38.8 million in the prior year, primarily driven by a surge in general and administrative expenses. The company transitioned its focus toward gold-leasing activities and digital assets, while successfully extinguishing $38 million in convertible debentures during the period.

Key figure
Net loss $17.5M
4:12 PM ET 10-Q
Financial Results GrabAGun Digital Holdings Inc. PEW ▶ Call

GrabAGun Digital Holdings Q3 2026 Results: Net Loss of $3.05M, Loss Narrows

GrabAGun Digital Holdings Inc. reported a net loss of $6.69 million for the nine months ended September 30, 2026, compared to a loss of $2.92 million in the prior year period, despite a 5.3% increase in net revenues to $70.38 million. The company's cash position decreased to $96.03 million from $110.40 million at year-end 2025, primarily due to increased capital expenditures and stock repurchases.

Key figure
Net loss $3.05M
4:12 PM ET 10-Q
Financial Results Remora Capital Corp REMC

Remora Capital Q3 2026 Results: Net Income $1.51M, Up 78.2% YoY

For the nine months ended September 30, 2026, Remora Capital Corp reported total investment income of $18.0 million and net investment income of $10.9 million. The company's Net Asset Value (NAV) per common share decreased from $9.98 at the end of 2025 to $9.75, primarily driven by $4.6 million in net unrealized depreciation on investments.

Key figure
Net income $1.51M · +78.2% YoY
4:12 PM ET 10-Q
Financial Results Prime Medicine, Inc. PRME

Prime Medicine Q3 2026 Results: Net Loss of $39M, Loss Narrows

Prime Medicine reported a net loss of $130.3 million for the nine months ended September 30, 2026, an improvement from the $155.1 million loss in the prior year period. Total revenue increased to $6.2 million, primarily driven by collaboration revenue from related parties, while total stockholders' equity significantly declined from $120.9 million to $8.4 million during the first nine months of 2026.

Key figure
Net loss $39M
4:12 PM ET 8-K
Financial Results Bolt Biotherapeutics, Inc. BOLT

Bolt Biotherapeutics Financial Results

Bolt Biotherapeutics reported Q3 2026 financial results and provided a business update following its acquisition of Prana Therapies and a concurrent $120 million private placement. The company is shifting its primary focus to the INSPIRE-built pipeline, specifically the Phase 2 development of PRA-216 for inflammatory indications, with a cash runway extending into 2028.

“Completing the Prana acquisition marks an important transformation for Bolt. With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”

Willie Quinn, President and Chief Executive Officer

“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”

Sheila Gujrathi, M.D., Chief Strategy Officer
4:12 PM ET 10-Q
Financial Results Parabilis Medicines, Inc. PBLS

Parabilis Medicines Q3 2026 Results: Net Loss of $44.5M, Loss Widens

Parabilis Medicines, Inc. is a clinical-stage biotechnology company that remains pre-revenue and has incurred significant losses since inception. As of November 9, 2026, the company had approximately 125.3 million total shares outstanding and is focused on advancing its Helicon discovery platform and lead product candidate, zolucatetide.

Key figure
Net loss $44.5M
4:12 PM ET 10-Q
Financial Results Crescent Biopharma, Inc. CBIO

Crescent Biopharma Q3 2026 Results: Net Loss of $37.7M, Loss Widens

Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing its lead program, CR-001, and other product candidates. The company has a limited operating history, has never generated revenue from product sales, and anticipates continued losses for the foreseeable future as it advances its clinical trials.

Key figure
Net loss $37.7M
4:12 PM ET Form 4
Insider Selling Universal Electronics Inc UEIC

Universal Electronics Insider Eric Singer Sells $581K of Stock

Eric Singer sold 102,827 shares of Universal Electronics Inc at $5.51 to $5.67 a share (average $5.65) in 2 transactions, worth $581K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 999,005 (-8.3%).

Value
$581K
Shares
102,827
Average price
$5.65
Holding change
-8.3%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:12 PM ET 8-K/A
M&A Deal Rank One Computing Corp ROC

Rank One Computing M&A Deal with Zuccaro Technical Consulting LLC

Rank One Computing Corporation (ROC) filed this amendment to provide required audited and pro forma financial statements following its completed acquisition of Zuccaro Technical Consulting LLC (ZTC). The transaction, which closed on August 31, 2026, involved ROC acquiring all issued and outstanding membership interests of ZTC from ZTC Holdco, Inc.

Counterparty
Zuccaro Technical Consulting LLC
4:12 PM ET 8-K
Financial Results BioCardia, Inc. BCDA

BioCardia Financial Results

BioCardia reported financial results for the third quarter ended September 30, 2026, and provided updates on its regulatory progress in Japan and the U.S. The company successfully completed pre-submission interactions with Japan's PMDA for its CardiAMP cell therapy and expects to file for FDA De Novo approval of its Helix delivery system in Q1 2027.

“We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency.”

Peter Altman, PhD, Chief Executive Officer of BioCardia

“In addition, in the coming months, we aim to be able to submit our Helix transendocardial delivery platform for FDA approval, which would be the first delivery system of its type approved in the United States. This promises to be an exciting year ahead.”

Peter Altman, PhD, Chief Executive Officer of BioCardia
4:12 PM ET Form 4
Insider Selling Motorola Solutions, Inc. MSI

Motorola Solutions EVP and CTO Mahesh Saptharishi Sells $1.53M of Stock

Mahesh Saptharishi, EVP and CTO, sold 2,998 shares of Motorola Solutions, Inc. at $511.08 to $515.24 a share (average $511.16) in 2 transactions, worth $1.53M in total on Nov 9, 2026. Shares held after the trade: 28,124 (-9.5%).

Value
$1.53M
Shares
2,998
Average price
$511.16
Role
EVP and CTO
Holding change
-9.5%
Trade date
Nov 9, 2026
4:12 PM ET 8-K
Financial Results Inve Technologies, Inc. INVE

Inve Technologies Financial Results

INVE Technologies reported Q3 2026 revenue of $3.1 million, a decrease from $5.0 million in the prior year due to the divestiture of its IoT business to Trackonomy. The company achieved GAAP net income of $0.6 million, driven by a gain on the asset sale, but currently has no commercial revenue following the transaction and is not providing future guidance.

Term
Q3 2026
4:12 PM ET 10-Q
Financial Results Flowers Foods Inc FLO

Flowers Foods Q3 2026 Results: Net Income $14.4M, Down 63.6% YoY

Flowers Foods reported a significant increase in cash and cash equivalents to $72.2 million as of October 10, 2026, compared to $12.1 million at the start of the fiscal year. The company is currently executing strategic initiatives including an ERP system upgrade and the acquisition of Simple Mills while managing risks related to independent distributor partner classifications.

Key figure
Net income $14.4M · -63.6% YoY
4:12 PM ET 8-K
Financial Results 4D Molecular Therapeutics, Inc. FDMT

4D Molecular Therapeutics Financial Results

4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.

“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”

David Kirn, MD, Co-founder, President and Chief Executive Officer
4:12 PM ET 8-K
Financial Results Pliant Therapeutics, Inc. PLRX

Pliant Therapeutics Financial Results

Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.

Term
Q3 2026

“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant
4:12 PM ET 10-Q
Financial Results Evommune, Inc. EVMN

Evommune Q3 2026 Results: Net Loss of $30.9M, Loss Widens

For the nine months ended September 30, 2026, Evommune, Inc. reported a net loss of $84.8 million, more than double the $40.6 million loss in the prior year period, primarily driven by increased research and development and general and administrative expenses. Total assets grew to $278.3 million as of September 30, 2026, supported by cash and investments totaling approximately $262.3 million.

Key figure
Net loss $30.9M
4:12 PM ET 8-K
Financial Results Macrogenics Inc MGNX

Macrogenics Financial Results

MacroGenics reported third quarter 2026 financial results, highlighting a cash position of $287.7 million and a cash runway extending through 2028. The company achieved several clinical milestones, including completing Phase 1 dose escalation for MGC028 and dosing the first patient in the Phase 1 study of MGC030.

Term
Q3 2026

“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”

Eric Risser, President and Chief Executive Officer

“Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”

Eric Risser, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.